• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

    4/28/25 8:30:00 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIRM alert in real time by email

    - 28-week data from Phase 2b VANTAGE PBC study highlighting improvements in itch and fatigue will be presented at EASL

    - Data from Mirum studies presented at DDW, EASL, and ESPGHAN congresses

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will present data at three upcoming medical congresses. Digestive Disease Week (DDW) will be held in San Diego, May 3-6, 2025. The European Association for the Study of the Liver (EASL) will take place May 7-10 in Amsterdam, the Netherlands. The 57th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting will follow May 14-17 in Helsinki, Finland. Data from Mirum's LIVMARLI and volixibat studies will be highlighted in oral and poster presentations during the congresses.

    "We are excited to see the continued evidence generated by Mirum medicines and product candidates across a number of settings," said Joanne Quan, MD, chief medical officer at Mirum. "In particular, we look forward to sharing updated data from the interim analysis of the VANTAGE study of volixibat in patients with pruritus due to PBC. We are encouraged by the positive results which show a meaningful decrease in pruritus that lasts for the duration of the placebo-controlled period."

    EASL – May 7-10, 2025

    Abstract #OS-059 (Oral): Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2B trial (VANTAGE): 28-week interim analysis

    Friday, May 9 from 8:30-8:45am CEST

    Immune-mediated and Cholestatic Diseases Session, McIntyre Room

    Presented by: Michael Heneghan, MD, MMedSc, FRCPI, King's College, London, UK

    New 28-week data were reported from the Phase 2 VANTAGE study evaluating volixibat in patients with cholestatic pruritus related to primary biliary cholangitis (PBC). Thirty-one patients with moderate-to-severe pruritus were randomized (20mg VLX=10, 80mg VLX=10, placebo=11). Data showed that volixibat led to early and significant reductions in PBC-associated cholestatic pruritus and were maintained throughout the duration of the study. Further, 70% of volixibat-treated patients had a ≥50% reduction in serum bile acid levels from baseline. Additionally, patients treated with volixibat experienced improvements in fatigue and sleep. No new safety signals were observed through 28 weeks of treatment. The most common treatment-emergent adverse event was diarrhea which was mild to moderate in severity and transient in nature.

    Additional data will be shared following the formal presentation on May 9.

    EASL Symposium

    Wednesday, May 7 from 1:30-2:30pm CEST

    Adult Cholestatic Liver Disease: Focusing on Clinical Outcomes and the Future of IBAT Inhibitors

    An archive of the symposium will be available following the event.

    DDW

    Oral Presentations

    Presentation 784: Volixibat for the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis: An Adaptive, Randomized, Placebo-controlled Phase 2B Trial (VANTAGE): Interim Results

    Monday, May 5 from 2:15-2:30pm PT

    Cholestatic Liver Disease session, Room 6C

    Presented by Mitchell Schiffman, MD, Bon Secours Liver Institute, Virginia, USA

    Presentation 1086: Comprehensive Analysis of Cholestasis Genetic Panel Results From 2016–2022 in Children and Young Adults: Insights into Diagnostic Yield

    Tuesday, May 6 from 10:00-10:15am PT

    Human and Experimental Cholestatic and Autoimmune Liver Diseases, Room 6F

    Presented by Brett Hoskins, DO, Indiana University School of Medicine, Indiana, USA

    Poster Presentations

    Poster Su1756: Genetic Insights Into PFIC-associated Genes in Unexplained Chronic Cholestasis and Liver Disease: Frequency and Implications of Variant Combinations

    Sunday, May 4 from 12:30-1:30pm PT

    Pediatric Hepatology Session, DDW Poster Hall, C-E

    Presented by Brett Hoskins, DO, Indiana University School of Medicine, Indiana, USA

    Poster Mo1627: Improvements in Pruritus, Serum Bile Acids, and Total Bilirubin Following Treatment with Maralixibat in Patients with Primary Sclerosing Cholangitis

    Monday, May 5 from 12:30-1:30pm PT

    Human and Experimental Cholestatic and Autoimmune Liver Diseases, DDW Poster Hall C-E

    Presented by Jessica Hochberg, MD, University of Miami Miller School of Medicine, Florida, USA

    ESPGHAN – May 14-17, 2025

    Oral presentations

    Abstract 1066: Improvements in pruritus are associated with growth in patients with progressive familial intrahepatic cholestasis: Data from the MARCH-ON trial

    Saturday, May 17 from 9:15-11:15am EEST

    Nutrition and Hepatology Session, Hall 3G

    Presented by Professor Richard Thompson, King's College, London, UK

    Abstract 1089: The relationship between serum bile acids and event-free survival following the use of maralixibat for progressive familial intrahepatic cholestasis (PFIC): Data from the MARCH/MARCH-ON trials

    Saturday, May 17 from 1:10-2:40pm EEST

    Hepatology Abstracts, Hall 3G

    Presented by Professor Richard Thompson, King's College, London, UK

    Abstract 1110: Improvements in pruritus after maralixibat treatment are associated with improved health-related quality of life for patients with cholestatic liver disease

    Saturday, May 17 from 1:10-2:40pm EEST

    Hepatology Abstracts, Hall 3G

    Presented by Dr. Emmanuel Gonzales, Hépatologie Pédiatrique, Hôpital Bicêtre, AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre, France

    Abstract 1098: Bile acid subspecies are correlated with pruritus and bilirubin improvement in PFIC patients treated with maralixibat: Data from MARCH and MARCH-ON

    Saturday, May 17 from 1:10-2:40pm EEST

    Hepatology Abstracts, Hall 3G

    Presented by Dr. Henkjan Verkade, University of Groningen, Beatrix Children's Hospital and University Medical Center Groningen, Netherlands

    Poster presentations

    Abstract 1102: Greater improvements in bilirubin were observed in pruritus responders after maralixibat treatment in patients with PFIC: data from the MARCH/MARCH-ON trials

    Friday, May 16 from 3:30-4:20pm EST

    General Hepatology 02 Session, e-Poster Station 08

    Presented by Professor Richard Thompson, King's College, London, UK

    Abstract 1094: Impact of long-term maralixibat treatment on concomitant medication use for the treatment of cholestatic pruritus in Alagille syndrome: Real-world experience in the United States

    Friday, May 16 from 3:30-4:20pm EEST

    General Hepatology 03 & Transplantation Session, e-Poster Station 09

    Presented by Dr. Tony Tokman, Mirum Pharmaceuticals, Inc., Foster City, California USA

    Abstract 1107: Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: Data from the MERGE study

    Friday, May 16 from 3:30-4:20pm EEST

    General Hepatology Session 02, e-Poster Station 08

    Presented by Dr. Emmanuel Gonzales, Hépatologie Pédiatrique, Hôpital Bicêtre, AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre, France

    ESPGHAN Symposium

    Thursday, May 15 from 12:45-1:45pm EEST

    Hall 3C

    Growing Knowledge and Evidence: Long-term impact of IBAT inhibition

    Full presentations will be available within the Publications and Presentations section on Mirum's website.

    About Volixibat

    Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver. Volixibat is currently being evaluated in Phase 2b studies for primary sclerosing cholangitis (PSC) (VISTAS study), and primary biliary cholangitis (PBC) (VANTAGE study). In June, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and improvements in fatigue for patients treated with volixibat. No new safety signals were observed, and the most common adverse event was diarrhea with all cases mild to moderate. Volixibat has been granted breakthrough therapy designation for the treatment of PBC.

    About LIVMARLI® (maralixibat) oral solution and LIVMARLI® (maralixibat) tablets

    LIVMARLI® (maralixibat) is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for two pediatric cholestatic liver diseases, in both liquid and tablet formulations. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older. It is also approved in the U.S. for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older and in Europe for the treatment of PFIC in patients three months of age and older. For more information for U.S. residents, please visit LIVMARLI.com.

    LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum's clinical trials section on the company's website.

    U.S. IMPORTANT SAFETY INFORMATION

    Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.

    LIVMARLI can cause side effects, including:

    Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.

    Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.

    A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.

    LIVMARLI is available in oral solution or tablet formulations and is taken by mouth 30 minutes before a meal. For Alagille syndrome, LIVMARLI is taken one time each day in the morning. For PFIC, LIVMARLI is taken two times each day. If you take the oral solution, use the oral dosing dispenser to measure your dose.

    US Prescribing Information

    EU SmPC

    Canadian Product Monograph

    About Mirum Pharmaceuticals, Inc.

    Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution/LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.

    LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease.

    CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.

    Mirum's late-stage pipeline includes two investigational treatments for several rare diseases.

    Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

    To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the anticipated presentations of data from Mirum's LIVMARLI and volixibat studies, including the VANTAGE study of volixibat in patients with pruritus due to PBC. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "will," "could," "can," "would," "potential," "hope," "opportunity," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum's business in general, the impact of macroeconomic and geopolitical developments, and the other risks described in Mirum's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission on February 26, 2025, and subsequent filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250428020303/en/

    Media Contact:

    Erin Murphy

    [email protected]



    Investor Contact:

    Andrew McKibben

    [email protected]

    Get the next $MIRM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MIRM

    DatePrice TargetRatingAnalyst
    5/19/2025$73.00Buy
    H.C. Wainwright
    4/17/2024$48.00Buy
    Stifel
    12/18/2023$60.00 → $58.00Buy
    H.C. Wainwright
    11/20/2023$37.00Overweight
    Analyst
    11/13/2023$60.00Overweight
    Morgan Stanley
    10/24/2023$50.00Overweight
    Cantor Fitzgerald
    10/17/2023$62.00Outperform
    Evercore ISI
    9/20/2023$70.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $MIRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $73.00

      5/19/25 8:53:13 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Mirum Pharmaceuticals with a new price target

      Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00

      4/17/24 7:27:53 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously

      12/18/23 11:54:26 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GLOBAL CONTROLLER Howe Jolanda converted options into 1,041 shares and sold $50,624 worth of shares (1,041 units at $48.63) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      7/3/25 6:48:47 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fairey William sold $155,091 worth of shares (3,203 units at $48.42), decreasing direct ownership by 56% to 2,500 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      6/13/25 4:18:54 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ramasastry Saira sold $377,843 worth of shares (8,203 units at $46.06) and exercised 2,500 shares at a strike of $14.12, closing all direct ownership in the company (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      6/4/25 4:11:47 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    SEC Filings

    See more
    • SEC Form 144 filed by Mirum Pharmaceuticals Inc.

      144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      6/11/25 4:05:18 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.

      SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      6/6/25 11:59:14 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Mirum Pharmaceuticals Inc.

      144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      6/3/25 5:07:25 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 2

      6/10/25 8:40:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

      5/19/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20th 2025 RBC Capital Markets Global Healthcare Conference Company presentation Wednesday, May 21st at 9:00 AM ET. Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information. About Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. is a biopharmaceutical compan

      5/14/25 4:05:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

      For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

      2/21/25 11:48:20 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 4:37:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:55:40 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:25:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

      5/19/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

      - 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris

      1/13/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MIRM
    Financials

    Live finance-specific insights

    See more
    • Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      - First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD

      5/7/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d

      4/30/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

      - 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 - CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. "2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue," said Chris Pee

      2/26/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 5:04:31 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/12/25 4:51:20 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $83,661 worth of shares (1,915 units at $43.69) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/10/25 5:12:58 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care